HIGHLIGHTS
- who: Yongliang Liu from the Center of Biological Therapy, Southwest Hospital, Army Medical University, Chongqing, China have published the research: CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia, in the Journal: (JOURNAL)
- what: The authors aimed to identify LSC-specific surface markers and uncover the underlying mechanism of AML LSCs. The authors focused on A2M not only because its expression level in CD9+ cells was high but also because activation of A2M signaling was reported to promote the proliferation and survival of cancer cells . The authors . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.